PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.
Biotest increases sales in the first half of 2024 by 35% to Euro 372 million – Biotech Investments
EQS-News: Biotest AG / Key word(s): Half Year Results/Half Year Results Biotest increases sales in the first half of 2024 by 35% to Euro 372